Prof Peter Krammer, M.D.
Professor Peter H. Krammer is one of the founders of Apogenix GmbH. He has pioneered research in the field of apoptosis, and his work has been key to understanding the pathways that control this mechanism of cell death. Professor Krammer is author of more that 300 scientific publications on apoptosis research. He holds numerous awards and acknowledgements, e.g. the Robert-Koch Prize, the German Cancer Prize, the Kitasato-Behring Prize, the Avery-Landsteiner Prize, the Jung Prize, and the 1st Class Order of Merit of the Federal Republic of Germany. Currently, Professor Krammer is coordinator of the research program Tumor Immunology of the German Cancer Research Center (DKFZ) in Heidelberg, Germany, and leads the center´s Division of Immunogenetics.
Prof Henning Walczak, Ph.D.
Henning Walczak is also a founder of Apogenix GmbH. He completed his master´s degree and Ph.D. work between 1990 and 1995 in Professor Peter Krammer’s laboratory at the German Cancer Research Center (DKFZ) in Heidelberg, Germany. In January 1996, Prof Walczak joined Immunex Corporation in Seattle, WA. After his return to Germany in 1998, he became group leader in the division headed by Professor Krammer at the German Cancer Research Center. In 1999, he was awarded the BioFuture Prize and was named Head of the BioFuture research group Apoptosis Regulation at the DKFZ. In addition to his research activities, he served as CEO for Apogenix Biotechnology AG, the predecessor company of Apogenix GmbH, from 2000 until 2004.
Since October 2007, he has been Professor at the Imperial College in London.
Ana Martin-Villalba, M.D., Ph.D.
Ana Martin-Villalba studied medicine at the University of Murcia in Spain and in Leeds (UK). She graduated in 1995 and received her M.D. from the University of Heidelberg in 1998 where she investigated the involvement of death ligands (CD95, TNF and TRAIL) in apoptosis taking place in the mammalian brain after a stroke. Following clinical and research periods at the University Hospital in Heidelberg and at the German Cancer Research Center in the division of Prof Krammer, Dr Martin-Villalba became Head of the Junior Group 'Molecular Neurobiology' at the DKFZ in 2006. In the same year, Dr Ana Martin-Villalba was awarded the Paul Ehrlich- and Ludwig Darmstaedter-Nachwuchspreis and the Heinz-Maier-Leibnitz Prize of the German Research Foundation. In 2007, Dr Martin-Villalba received the Walther and Christine Richtzenhain Award for her research on the involvement of CD95-mediated programmed cell death involved in CNS injury.
